NRx Pharmaceuticals
Tracked across 4 events · 29 articles · First seen Apr 15, 2026 · Last active Aug 07, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: NRx Pharmaceuticals incorporated NRx Defense Systems, Inc. as a new R&D subsidiary to develop neuroplastic treatments for military and first responders, which could open new revenue streams and enhance its market position.
Apr 15, 2026 · 7 articles
Business
Impact: NRx Pharmaceuticals announced the pricing of a public offering of its common stock, aiming to raise approximately $20.0 million for working capital and general corporate purposes to support its growth. This offering will dilute existing shareholders but provide capital for the company's operations and development of its therapeutics.
Jun 02, 2026 · 10 articles
Tech
Impact: NRx Pharmaceuticals, through its subsidiary MiNK Therapeutics, has begun treating patients with the Zeta TMS Navigation System, advancing its interventional psychiatry platform and supporting its planned clinical trials. This enhances its market position in CNS disorder treatments.
Jun 25, 2026 · 6 articles
Regulatory
NRx Pharmaceuticals, Inc. announced that the U.S. United States — Food and Drug Administration (FDA) has completed its first-cycle review of the company's Abbreviated New Drug Application (ANDA) for preservative-free ketamine. The company will host…
Impact: NRx Pharmaceuticals is the central entity; the FDA's review completion is a key milestone for its lead product candidate, potentially improving its commercial prospects and stock valuation.
Aug 07, 2026 · 6 articles
40
NRx Pharmaceuticals scheduled conference callNRx Pharmaceuticals FDA ANDA Review
ERGEN INTELLIGENCE
Track NRx Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard